(MedPage Today) — The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the treatment’s place in the nation…
Source link : https://www.medpagetoday.com/infectiousdisease/hivaids/117629
Author :
Publish date : 2025-09-24 20:25:00
Copyright for syndicated content belongs to the linked Source.
